← FDA ENFORCEMENT
D-1056-2023Class II

Central Admixture Pharmacy Services Inc

Recalling firm
Central Admixture Pharmacy Services Inc
Product type
Drug
Status
Terminated
Report date
2023-08-09
Distribution
Nationwide in the USA
Firm state
CA
Product quantity
12,239 syringes
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Environmental Monitoring
Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Product description

succinylcholine, 200 mg/10 mL, (20 mg/mL), 10 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6011-2

Code / lot info

Lot: 17-270532, 17-270538, Exp, 7/16/2023; 17-270601, Exp, 7/17/2023; 17-270888, Exp, 7/20/2023; 17-271680, Exp, 8/2/2023; 17-271828, Exp, 8/6/2023; 17-271959, Exp, 8/8/2023; 17-272232, 17-272239, Exp, 8/13/2023; 17-272338, Exp, 8/15/2023; 17-272452, 17-272463, Exp, 8/16/2023; 17-272551, 17-272557, Exp, 8/17/2023; 17-272800, 17-272819, Exp, 8/22/2023; 17-272889, 17-272917, Exp, 8/23/2023; 17-272978, Exp, 8/24/2023; 17-273077, Exp, 8/28/2023; 17-273166, Exp, 8/29/2023; 17-273604, Exp, 9/5/2023; 17-273729, 17-273731, Exp, 9/6/2023; 17-273854, 17-273870, Exp, 9/10/2023;

Other recalls SPEQ maps to Environmental Monitoring
2026-07-22Class IArgon Medical Devices, Inc2026-07-22Class IIOlympus Corporation of the Americas2026-07-22Class IIChiesi USA, Inc.2026-07-22Class IICareFusion 213, LLC
See all Environmental Monitoring recalls →

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.